0M2N
:LSE

Add to watchlist
35,65 €
Last updated:10/15/2021
0M2N: LSE
35,65 €
Orion Oyj Series A

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comta…

P/E ratio
26.21x
vs. 0.00x forward
Stock volatility (Beta)
past 12 months
Become our supporter to unlock all data!
Company results
Qtr
Ann
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
Create free account to unlock
Cashflow
Sum up money going in and out company
Create free account to unlock
Total liabilities
All combined debts and obligations
Create free account to unlock
Company profile
CEO
Mr. Timo Lappalainen
Market capitalization
Mid (4.57B)